Voyager Therapeutics Stock Performance
| VYGR Stock | USD 5.75 0.06 1.05% |
Voyager Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 3.11, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Voyager Therapeutics will likely underperform. Voyager Therapeutics right now has a risk of 5.63%. Please validate Voyager Therapeutics maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to decide if Voyager Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Voyager Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable technical and fundamental indicators, Voyager Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.05 | Five Day Return (8.29) | Year To Date Return (36.11) | Ten Year Return (67.61) | All Time Return (67.61) |
1 | Acquisition by Jorgensen Nathan D. of 80000 shares of Voyager Therapeutics subject to Rule 16b-3 | 10/01/2024 |
2 | Disposition of 5999 shares by Fahey Sandell Jacquelyn of Voyager Therapeutics at 5.82 subject to Rule 16b-3 | 10/02/2024 |
3 | Strength Seen in Voyager Therapeutics Can Its 17.5 percent Jump Turn into More Strength | 10/07/2024 |
4 | Disposition of 1266 shares by Todd Carter of Voyager Therapeutics at 7.18 subject to Rule 16b-3 | 10/11/2024 |
5 | Voyager Therapeutics Rating Increased to Buy at StockNews.com | 10/15/2024 |
6 | Voyager Therapeutics Upgraded by Leerink Partnrs to Strong-Buy | 10/17/2024 |
7 | Patriot Financial Group Insurance Agency LLC Has 801,000 Stock Holdings in Voyager Therapeutics, Inc. | 10/29/2024 |
8 | Voyager Therapeutics Inc Q3 2024 Earnings Revenue Soars to 24.63M, EPS Loss of 0. ... | 11/12/2024 |
9 | Declining Stock and Decent Financials Is The Market Wrong About Voyager Therapeutics, Inc. - Yahoo Finance | 11/14/2024 |
10 | A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts - Benzinga | 12/02/2024 |
11 | Voyager Therapeutics, Inc. Receives 17.00 Consensus PT from Brokerages - MarketBeat | 12/17/2024 |
| Begin Period Cash Flow | 100.5 M |
Voyager |
Voyager Therapeutics Relative Risk vs. Return Landscape
If you would invest 604.00 in Voyager Therapeutics on September 24, 2024 and sell it today you would lose (29.00) from holding Voyager Therapeutics or give up 4.8% of portfolio value over 90 days. Voyager Therapeutics is currently generating 0.0773% in daily expected returns and assumes 5.6322% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Voyager, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Voyager Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Voyager Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Voyager Therapeutics, and traders can use it to determine the average amount a Voyager Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0137
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | VYGR | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.63 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Voyager Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Voyager Therapeutics by adding it to a well-diversified portfolio.
Voyager Therapeutics Fundamentals Growth
Voyager Stock prices reflect investors' perceptions of the future prospects and financial health of Voyager Therapeutics, and Voyager Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Voyager Stock performance.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0157 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 14.36 M | ||||
| Shares Outstanding | 54.63 M | ||||
| Price To Earning | 5.62 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 1.92 X | ||||
| Revenue | 250.01 M | ||||
| EBITDA | 126.45 M | ||||
| Cash And Equivalents | 148.06 M | ||||
| Cash Per Share | 3.83 X | ||||
| Total Debt | 20.29 M | ||||
| Debt To Equity | 0.40 % | ||||
| Book Value Per Share | 6.06 X | ||||
| Cash Flow From Operations | 77.92 M | ||||
| Earnings Per Share | 0.66 X | ||||
| Total Asset | 351.28 M | ||||
| Retained Earnings | (261.18 M) | ||||
| Current Asset | 195.89 M | ||||
| Current Liabilities | 23.93 M | ||||
About Voyager Therapeutics Performance
Assessing Voyager Therapeutics' fundamental ratios provides investors with valuable insights into Voyager Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Voyager Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.Things to note about Voyager Therapeutics performance evaluation
Checking the ongoing alerts about Voyager Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Voyager Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Voyager Therapeutics had very high historical volatility over the last 90 days | |
| About 66.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Voyager Therapeutics, Inc. Receives 17.00 Consensus PT from Brokerages - MarketBeat |
- Analyzing Voyager Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Voyager Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Voyager Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Voyager Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Voyager Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Voyager Therapeutics' stock. These opinions can provide insight into Voyager Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.